TY - JOUR
T1 - Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature
AU - Saenger, Paul
AU - Attie, Kenneth M.
AU - Dimartino-Nardi, Joan
AU - Hintz, Raymond
AU - Frahm, Lindley
AU - Frane, James W.
AU - Johanson, A. J.
AU - Baptista, J.
AU - Kuntze, J.
AU - Blizzard, R.
AU - Cara, J.
AU - Chernausek, S.
AU - Geffner, M.
AU - Gertner, J.
AU - Hopwood, N.
AU - Kaplan, S.
AU - Lippe, B.
AU - Plotnick, L.
AU - Rogol, A.
PY - 1998
Y1 - 1998
N2 - In a multicenter study the metabolic effects of 5 yr of GH therapy in children with idiopathic short stature were evaluated. Patients received 0.3 mg/kg · week recombinant human GH. Of the 121 patients who entered the study, data for 62 were analyzed at the final 5 yr point. Routine laboratory determinations were available for all 62 subjects at the 5 yr point. Special laboratory determinations, such as postprandial glucose and insulin, were available for only a subset of patients. Mean insulin-like growth factor I levels rose to 283 ± 101 μg/L, within the normal range using age- appropriate reference standards. T4, cholesterol, triglycerides, blood chemistries, and blood pres- sure showed no significant changes during the 5- yr period. Mean baseline and 2-h postprandial glucose levels remained unchanged. Both fasting and postprandial insulin levels rose substantively from low normal levels to the normal range (median, 4.9-43 mU/L). Mean hemoglobin A(1c) levels remained within the normal range throughout the study. In summary, careful monitoring has not revealed any currently discernible metabolic side-effects of clinical significance after GH therapy in this 5-yr study of children with idiopathic short stature.
AB - In a multicenter study the metabolic effects of 5 yr of GH therapy in children with idiopathic short stature were evaluated. Patients received 0.3 mg/kg · week recombinant human GH. Of the 121 patients who entered the study, data for 62 were analyzed at the final 5 yr point. Routine laboratory determinations were available for all 62 subjects at the 5 yr point. Special laboratory determinations, such as postprandial glucose and insulin, were available for only a subset of patients. Mean insulin-like growth factor I levels rose to 283 ± 101 μg/L, within the normal range using age- appropriate reference standards. T4, cholesterol, triglycerides, blood chemistries, and blood pres- sure showed no significant changes during the 5- yr period. Mean baseline and 2-h postprandial glucose levels remained unchanged. Both fasting and postprandial insulin levels rose substantively from low normal levels to the normal range (median, 4.9-43 mU/L). Mean hemoglobin A(1c) levels remained within the normal range throughout the study. In summary, careful monitoring has not revealed any currently discernible metabolic side-effects of clinical significance after GH therapy in this 5-yr study of children with idiopathic short stature.
UR - http://www.scopus.com/inward/record.url?scp=7844250828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7844250828&partnerID=8YFLogxK
U2 - 10.1210/jc.83.9.3115
DO - 10.1210/jc.83.9.3115
M3 - Article
C2 - 9745413
AN - SCOPUS:7844250828
SN - 0021-972X
VL - 83
SP - 3115
EP - 3120
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -